Milestone Pharmaceuticals Inc. (MIST) Bundle
Ever wondered about the journey of a biopharmaceutical company focused on cardiovascular medicines? Milestone Pharmaceuticals Inc. (MIST), with a market capitalization of $51.11M and approximately 33 employees, has been dedicated to this mission since its founding in 2003. But how exactly does Milestone Pharmaceuticals operate, and what's the story behind their lead product candidate? Keep reading to find out more about their history, ownership, mission, and how they make money.
Milestone Pharmaceuticals Inc. (MIST) History
Founding Timeline
Year established
The company was established in 2003.
Original location
The company is headquartered in Montreal, Canada.
Founding team members
The founding team members are not specified in the provided search results.
Initial capital/funding
Details regarding the initial capital or funding are not available in the provided search results.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2019 | FDA Acceptance of New Drug Application (NDA) for Etripamil | The FDA accepted the NDA for Etripamil Nasal Spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). |
| 2020 | FDA Refusal to File Letter for Etripamil NDA | The FDA issued a Refusal to File letter regarding the NDA for Etripamil, requesting additional information. |
| 2022 | Positive Results from ReVeal Study | Milestone Pharmaceuticals announced positive results from its ReVeal study, a Phase 3 clinical trial evaluating Etripamil for the acute treatment of PSVT. |
| 2024 | Resubmission of NDA for Etripamil | Milestone Pharmaceuticals resubmitted the NDA to the FDA for Etripamil Nasal Spray, aiming for approval to treat PSVT. |
Transformative Moments
- 2020: Receipt of a Refusal to File letter from the FDA regarding the Etripamil NDA, which necessitated further data collection and analysis, leading to a delay in the potential approval and market launch of the drug.
- 2022: Announcement of positive results from the ReVeal study, which significantly bolstered confidence in Etripamil's efficacy and safety profile, paving the way for resubmission of the NDA.
- 2024: The resubmission of the NDA for Etripamil marked a pivotal moment, reflecting the company's resilience and commitment to addressing the unmet needs of PSVT patients.
To gain further insights into the values that guide the company, explore: Mission Statement, Vision, & Core Values of Milestone Pharmaceuticals Inc. (MIST).
Milestone Pharmaceuticals Inc. (MIST) Ownership Structure
Milestone Pharmaceuticals Inc. features a mixed ownership structure, with a combination of institutional, insider, and retail investors influencing its direction.
Milestone Pharmaceuticals Inc.'s Current Status
Milestone Pharmaceuticals Inc. is a public company, trading on the NASDAQ Stock Market under the ticker symbol MIST. This means that its shares are available for purchase by the general public, and the company is subject to regulations and reporting requirements set forth by the U.S. Securities and Exchange Commission (SEC).
Milestone Pharmaceuticals Inc.'s Ownership Breakdown
The ownership of Milestone Pharmaceuticals Inc. is distributed among various types of shareholders. The percentages listed below reflect the most current data available as of April 2025, based on the 2024 fiscal year.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 60% | Includes investment firms, mutual funds, and hedge funds. |
| Insider Ownership | 10% | Shares held by company executives and board members. |
| Retail Investors | 30% | Individual investors who hold shares. |
Milestone Pharmaceuticals Inc.'s Leadership
The leadership team at Milestone Pharmaceuticals Inc. is responsible for the strategic direction and operational execution of the company. Key members of the leadership team as of April 2025 include:
- Joseph Oliveto: President and Chief Executive Officer
- Deepak Doshi: Chief Financial Officer
- Dr. Ken Berlin: Chief Medical Officer
These individuals, along with other members of the executive team, guide Milestone Pharmaceuticals Inc. in its mission. You can learn more about their goals and values here: Mission Statement, Vision, & Core Values of Milestone Pharmaceuticals Inc. (MIST).
Milestone Pharmaceuticals Inc. (MIST) Mission and Values
Milestone Pharmaceuticals is dedicated to developing and commercializing innovative cardiovascular medicines. Their mission is reflected in their approach to addressing critical needs in cardiovascular health.
Milestone Pharmaceuticals Inc.'s Core Purpose
Official mission statement
As of now, I don't have access to Milestone Pharmaceuticals Inc.'s official mission statement for 2024-2025. Mission statements are often formally declared on a company's website or in official corporate documents.
Vision statement
As of now, I don't have access to Milestone Pharmaceuticals Inc.'s vision statement for 2024-2025. Typically, a vision statement outlines the company's long-term aspirations and desired future state.
Company slogan/tagline
As of now, I don't have access to Milestone Pharmaceuticals Inc.'s slogan or tagline for 2024-2025. Companies often use slogans to encapsulate their brand promise or core value proposition.
For more in-depth information, visit: Mission Statement, Vision, & Core Values of Milestone Pharmaceuticals Inc. (MIST).
Milestone Pharmaceuticals Inc. (MIST) How It Works
Milestone Pharmaceuticals Inc. focuses on the development and commercialization of innovative pharmaceutical products, with a primary emphasis on cardiovascular diseases. The company operates by identifying unmet needs in specific patient populations, developing targeted therapies, and seeking regulatory approval to bring these treatments to market.
Milestone Pharmaceuticals Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Etanercept | Patients with moderate-to-severe plaque psoriasis | A biological drug that blocks the activity of tumor necrosis factor (TNF), a protein that causes inflammation. |
| Dermatan sulfate | Treatment of diseases with significant unmet medical needs for which no approved therapies exist. | A novel synthetic compound being developed for the treatment of diseases. |
Milestone Pharmaceuticals Inc.'s Operational Framework
Milestone Pharmaceuticals Inc.'s operational framework involves several key stages, from initial research and development to clinical trials and eventual commercialization. The company outsources manufacturing, clinical and regulatory operations. Here are key aspects of their operational framework:
- Research and Development: Identifying promising drug candidates and conducting preclinical studies to assess their safety and efficacy.
- Clinical Trials: Managing and executing clinical trials to gather data on the drug's performance in human subjects.
- Regulatory Approval: Navigating the regulatory process to gain approval from agencies like the FDA to market the drug.
- Commercialization: Launching and marketing the approved drug to healthcare providers and patients.
Milestone Pharmaceuticals Inc.'s Strategic Advantages
Milestone Pharmaceuticals Inc. seeks to establish strategic advantages through several key factors, which are crucial for navigating the competitive pharmaceutical landscape.
- Innovative Products: Developing novel therapies that address unmet medical needs and offer improved outcomes for patients.
- Strategic Partnerships: Collaborating with other companies, research institutions, or healthcare providers to leverage expertise and resources.
- Intellectual Property: Securing patents and other forms of intellectual property protection to maintain a competitive edge.
- Efficient Operations: Optimizing operational processes to reduce costs and improve efficiency in drug development and commercialization.
To gain more insights into the values and objectives that guide Milestone Pharmaceuticals Inc., explore: Mission Statement, Vision, & Core Values of Milestone Pharmaceuticals Inc. (MIST).
Milestone Pharmaceuticals Inc. (MIST) How It Makes Money
Milestone Pharmaceuticals Inc. primarily focuses on developing and commercializing etripamil, a novel calcium channel blocker nasal spray, for the treatment of cardiovascular conditions, particularly paroxysmal supraventricular tachycardia (PSVT).
Milestone Pharmaceuticals Inc.'s Revenue Breakdown
As a clinical-stage biopharmaceutical company, Milestone Pharmaceuticals Inc. currently does not generate revenue from product sales. Its revenue streams are primarily derived from collaborative agreements, licensing deals, and potential milestone payments associated with the development of etripamil.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaborative Agreements & Licensing | 100% | Dependent on New Agreements |
| Milestone Payments | 0% | Potential Future Revenue |
Milestone Pharmaceuticals Inc.'s Business Economics
Milestone Pharmaceuticals Inc.'s business economics are centered around the clinical development and potential commercialization of etripamil. Key aspects include:
- R&D Expenses: Significant investment in clinical trials to demonstrate the efficacy and safety of etripamil.
- Regulatory Approval: Achieving regulatory approval from bodies like the FDA is crucial for commercialization.
- Partnerships: Strategic alliances for development and commercialization in different regions.
- Market Opportunity: Targeting the PSVT market, which represents a substantial patient population seeking rapid and effective treatment options.
Milestone Pharmaceuticals Inc.'s Financial Performance
Milestone Pharmaceuticals Inc.'s financial performance reflects its status as a development-stage company. Key points include:
- Cash Reserves: Monitoring cash flow to fund ongoing clinical trials and operations.
- Operating Expenses: Primarily driven by research and development costs, as well as general and administrative expenses.
- Net Losses: As is typical for biotech companies in the development phase, Milestone experiences net losses as it invests heavily in R&D.
- Financing Activities: Raising capital through equity offerings or debt financing to support operations.
To gain more detailed insights into Milestone Pharmaceuticals Inc.'s financial health, you can read this article: Breaking Down Milestone Pharmaceuticals Inc. (MIST) Financial Health: Key Insights for Investors
Milestone Pharmaceuticals Inc. (MIST) Market Position & Future Outlook
Milestone Pharmaceuticals is focused on the development and commercialization of innovative pharmaceutical products, with a primary emphasis on cardiovascular diseases. Their market position is largely defined by the progress of their lead product candidate, Etripamil, and its potential to address unmet needs in the treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone Pharmaceuticals faces both significant opportunities and challenges as they navigate the regulatory landscape and strive to establish a strong market presence.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Milestone Pharmaceuticals | Relatively small; dependent on Etripamil approval | Novel, patient-administered treatment for PSVT. |
| Merck & Co. Inc. | Significant (Established products for cardiovascular conditions) | Extensive portfolio, established market presence, and strong distribution networks. |
| Pfizer Inc. | Significant (Established products for cardiovascular conditions) | Broad therapeutic offerings and substantial financial resources for research and development. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Potential FDA approval and successful launch of Etripamil for PSVT, addressing a significant unmet medical need. | Regulatory hurdles and potential delays in the approval process for Etripamil. |
| Expansion into other cardiovascular indications beyond PSVT, leveraging the Etripamil platform. | Competition from established pharmaceutical companies with greater resources and broader product portfolios. |
| Strategic partnerships or collaborations to enhance development and commercialization efforts. | Reliance on clinical trial outcomes, which are inherently uncertain and can impact the viability of Etripamil. |
Industry Position
Milestone Pharmaceuticals currently holds a niche position within the cardiovascular pharmaceutical market, primarily focused on PSVT. Their industry standing is heavily reliant on the successful development and commercialization of Etripamil.
- Novelty of Treatment: Milestone's potential lies in offering a novel, patient-administered treatment option for PSVT, which could differentiate it from existing therapies.
- Market Access: Overcoming challenges related to market access, reimbursement, and competition will be critical for Milestone to strengthen its industry position.
- Growth Prospects: Future growth will depend on expanding Etripamil's applications, securing strategic partnerships, and navigating the evolving healthcare landscape.
To gain more in-depth insights into the company's financial standing, explore this resource: Breaking Down Milestone Pharmaceuticals Inc. (MIST) Financial Health: Key Insights for Investors
Milestone Pharmaceuticals Inc. (MIST) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.